{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:44:49Z","timestamp":1766551489371,"version":"3.44.0"},"reference-count":179,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSAMC"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The accumulation of tau-containing neurofibrillary tangles and beta-amyloid\ndeposits has been identified as the hallmark of Alzheimer's disease. Alzheimer's disease (AD) is\na hereditary and neurological condition that can result in non-amnestic cognitive decline in less\ncommon forms and amnestic memory loss in its classic form. While Alzheimer's disease is the\nmost prevalent cause of memory loss in middle-aged and older adults, other neurodegenerative\nand cerebrovascular disorders can have an impact on the disease's clinical course. Designing\nmulti-target-directed ligands (MTDLs) is a very promising modern approach. This methodology\nwas designed specifically for treating disorders with complex pathological mechanisms.\nAmong these disorders is Alzheimer's disease (AD), which is currently the most prevalent\nmultifactorial neurodegenerative illness. Increased amounts of the amyloid \u03b2peptide (A\u03b2) and\nhyperphosphorylated tau protein, together with the loss of neurons and synapses, are linked to\nAlzheimer's disease (AD). Additionally, there is evidence that the pathophysiology of this\ncondition is influenced by oxidative stress, metal ion dysregulation, inflammation, and failure\nof the cell cycle regulatory system. Since Alzheimer's disease (AD) is a multi-factor illness,\nthere are many attractive targets for the development of anti-AD medications. These molecules\ncan be useful in treating AD since they are multi-target-directed. This review focuses on the\ndiscovery of dual and multi-acting anti-AD drug candidates, especially hybrids made by\ncombining chemically active moieties that function against distinct targets. The first group of\nsubstances consists of cholinesterase inhibitors with extra properties or those that function as\nmultiple binding site inhibitors. Natural products also provide numerous options for slowing the\nprogression and symptoms of many diseases, including Alzheimer's Meanwhile, Natural\nchemical structures with the following characteristics: alkaloids, sterols, triterpenes, tannins,\nflavonoids, polyphenols, and antioxidants as well as anti-inflammatory and anti-amyloidogenic\nproperties. We provide an overview of Alzheimer's disease pathophysiology and therapy targets\nin this study. We also show several isolated chemicals and medicinal plants that are used to\ntreat and prevent the symptoms of Alzheimer's disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0118715249333381241012073557","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:13:56Z","timestamp":1729667636000},"page":"454-474","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Emerging Targets Identification in Reducing Risk of Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0358-0890","authenticated-orcid":true,"given":"Saurabh","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\n203201, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-7814","authenticated-orcid":true,"given":"Kalpana","family":"Rahate","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\n203201, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2617-277X","authenticated-orcid":true,"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\n203201, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","volume":"56","author":"Castellani R.J.","year":"2010","unstructured":"Castellani R.J.; Rolston R.K.; Smith M.A.; Alzheimer Disease. Dis Mon  2010,56(9),484-546","journal-title":"Dis Mon"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"Knopman D.S.","year":"2021","unstructured":"Knopman D.S.; Amieva H.; Petersen R.C.; Ch\u00e9telat G.; Holtzman D.M.; Hyman B.T.; Nixon R.A.; Jones D.T.; Alzheimer disease. Nat Rev Dis Primers  2021,7(1),33","journal-title":"Nat Rev Dis Primers"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/CON.0000000000000307","volume":"22","author":"Apostolova L.G.","year":"2016","unstructured":"Apostolova L.G.; Alzheimer Disease. Continuum (Minneap Minn)  2016,22,419-434","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A.","year":"2011","unstructured":"Serrano-Pozo A.; Frosch M.P.; Masliah E.; Hyman B.T.; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med  2011,1(1),a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-802395-2.00023-7","volume":"145","author":"Calderon-Garcidue\u00f1as A.L.","year":"2018","unstructured":"Calderon-Garcidue\u00f1as A.L.; Duyckaerts C.; Alzheimer disease. Handb Clin Neurol  2018,145,325-337","journal-title":"Handb Clin Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"a006239","DOI":"10.1101\/cshperspect.a006239","volume":"2","author":"Mayeux R.","year":"2012","unstructured":"Mayeux R.; Stern Y.; Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med  2012,2(8),a006239","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"Reitz C.","year":"2011","unstructured":"Reitz C.; Brayne C.; Mayeux R.; Epidemiology of Alzheimer disease. Nat Rev Neurol  2011,7(3),137-152","journal-title":"Nat Rev Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.nurpra.2017.10.014","volume":"14","author":"Ulep M.G.","year":"2018","unstructured":"Ulep M.G.; Saraon S.K.; McLea S.; Alzheimer Disease. J Nurse Pract  2018,14(3),129-135","journal-title":"J Nurse Pract"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1001\/jama.287.18.2335","volume":"287","author":"Cummings J.L.","year":"2002","unstructured":"Cummings J.L.; Cole G.; Alzheimer disease. JAMA  2002,287(18),2335-2338","journal-title":"JAMA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)60607-8","volume":"42","author":"Smith M.A.","year":"1998","unstructured":"Smith M.A.; Alzheimer disease. Int Rev Neurobiol  1998,42,1-54","journal-title":"Int Rev Neurobiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"a011585","DOI":"10.1101\/cshperspect.a011585","volume":"2","author":"Holtzman D.M.","year":"2012","unstructured":"Holtzman D.M.; Mandelkow E.; Selkoe D.J.; Alzheimer Disease in 2020. Cold Spring Harb Perspect Med  2012,2(11),a011585","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00401-015-1390-7","volume":"129","author":"Duyckaerts C.","year":"2015","unstructured":"Duyckaerts C.; Braak H.; Brion J.P.; Bu\u00e9e L.; Del Tredici K.; Goedert M.; Halliday G.; Neumann M.; Spillantini M.G.; Tolnay M.; Uchihara T.; PART is part of Alzheimer disease. Acta Neuropathol  2015,129(5),749-756","journal-title":"Acta Neuropathol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00002093-199501002-00005","volume":"9","author":"Geula C.","year":"1995","unstructured":"Geula C.; Mesulam M.M.; Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord  1995,9(Suppl. 2),23-28","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=14","author":"Kumar A.","year":"2018","unstructured":"Kumar A.; Sidhu J.; Goyal A.; Tsao J.W.;  StatPearls  2018","journal-title":"StatPearls"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell  2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=16","first-page":"155","author":"Geldmacher D.S.","year":"2009","unstructured":"Geldmacher D.S.;  In: The American Psychiatric Publishing textbook of Alzheimer disease and other dementias  2009,155-172","journal-title":"In: The American Psychiatric Publishing textbook of Alzheimer disease and other dementias"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7326\/0003-4819-109-4-298","volume":"109","author":"Friedland R.P.","year":"1988","unstructured":"Friedland R.P.; Koss E.; Haxby J.V.; Grady C.L.; Luxenberg J.; Schapiro M.B.; Kaye J.; NIH conference. Alzheimer disease: Clinical and biological heterogeneity. Ann Intern Med  1988,109(4),298-311","journal-title":"Ann Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jsps.2022.10.004","volume":"30","author":"Alhazmi H.A.","year":"2022","unstructured":"Alhazmi H.A.; Albratty M.; An update on the novel and approved drugs for Alzheimer disease. Saudi Pharm J  2022,30(12),1755-1764","journal-title":"Saudi Pharm J"},{"key":"ref=19","first-page":"208","volume":"35","author":"Casey D.A.","year":"2010","unstructured":"Casey D.A.; Antimisiaris D.; O\u2019Brien J.; Drugs for Alzheimer\u2019s disease: Are they effective? PandT  2010,35(4),208-211","journal-title":"PandT"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/DDDT.S41431","volume":"7","author":"Ghezzi L.","year":"2013","unstructured":"Ghezzi L.; Scarpini E.; Galimberti D.; Disease-modifying drugs in Alzheimer\u2019s disease. Drug Des Devel Ther,  2013,7,1471-1478","journal-title":"Drug Des Devel Ther,"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0079-6123(08)62431-0","volume":"98","author":"Giacobini E.","year":"1993","unstructured":"Giacobini E.;   1993,98,447-454"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138161209787315585","volume":"15","author":"Bolognesi M.","year":"2009","unstructured":"Bolognesi M.; Rosini M.; Andrisano V.; Bartolini M.; Minarini A.; Tumiatti V.; Melchiorre C.; MTDL design strategy in the context of Alzheimer\u2019s disease: From lipocrine to memoquin and beyond. Curr Pharm Des  2009,15(6),601-613","journal-title":"Curr Pharm Des"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fnins.2016.00205","volume":"10","author":"Unzeta M.","year":"2016","unstructured":"Unzeta M.; Esteban G.; Bolea I.; Fogel W.A.; Ramsay R.R.; Youdim M.B.H.; Tipton K.F.; Marco-Contelles J.; Multi-target directed donepezil-like ligands for Alzheimer\u2019s disease. Front Neurosci  2016,10,205","journal-title":"Front Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/9781608057221113010004","volume":"1","author":"Wright J.W.","year":"2013","unstructured":"Wright J.W.; Harding J.W.; The development of multi-target-directed ligands (MTDL) to treat Alzheimer\u2019s disease. Front Clin Drug Res Alzheimer Disord  2013,1,86-108","journal-title":"Front Clin Drug Res Alzheimer Disord"},{"key":"ref=25","first-page":"22","author":"Bartoli\u0107 M.","year":"2022","unstructured":"Bartoli\u0107 M.; Mato\u0161evi\u0107 A.; Bosak A.; Evaluation of 4-\naminoquinolines as potential MTDL ligands for the treatment of\nAlzheimer's disease. In: Book of Abstracts of Joint IUBMB\/FEBS\nAdvanced Lecture Course \"Molecular targets for anti-aging interventions\";\nFEBS\/IUBMB,  2022,22"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1039\/9781849731072-00213","volume":"2","author":"Bolognesi M.L.","year":"2010","unstructured":"Bolognesi M.L.; Minarini A.; Melchiorre C.; Chapter 25: Discovery\nof memoquin, a multitarget-Directed Ligand (MTDL) for the\ntreatment of Alzheimer's disease. In: Emerging Drugs and Targets\nfor Alzheimer's Disease; Martinez, A., Ed.; RSC Publishing,  2010,2,213-227"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1080\/14756366.2022.2126464","volume":"37","author":"Lamie P.F.","year":"2022","unstructured":"Lamie P.F.; Abdel-Fattah M.M.; Philoppes J.N.; Design and synthesis of new indole drug candidates to treat Alzheimer\u2019s disease and targeting neuro-inflammation using a multi-target-directed ligand (MTDL) strategy. J Enzyme Inhib Med Chem  2022,37(1),2660-2678","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cbpa.2009.04.619","volume":"13","author":"Bolognesi M.L.","year":"2009","unstructured":"Bolognesi M.L.; Matera R.; Minarini A.; Rosini M.; Melchiorre C.; Alzheimer\u2019s disease: New approaches to drug discovery. Curr Opin Chem Biol  2009,13(3),303-308","journal-title":"Curr Opin Chem Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1570159X1203140511153200","volume":"12","author":"Simone Tranches Dias K.","year":"2014","unstructured":"Simone Tranches Dias K.; Viegas C.; Jr Multi-target directed drugs: A modern approach for design of new drugs for the treatment of Alzheimer\u2019s disease. Curr Neuropharmacol  2014,12(3),239-255","journal-title":"Curr Neuropharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.lfs.2018.06.025","volume":"207","author":"Wenzel T.J.","year":"2018","unstructured":"Wenzel T.J.; Klegeris A.; Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer\u2019s disease. Life Sci  2018,207,314-322","journal-title":"Life Sci"},{"author":"George N.","key":"ref=31","doi-asserted-by":"publisher","unstructured":"George N.; Khan S.; Balushi K.; Abukhader M.; Sabahi B.; Synthesis, molecular docking, antioxidant and cholinesterase inhibitory\nactivity of coumarin based tri-hybridized molecules: An\nMTDL approach for the development of anti-Alzheimer drugs.\nProceedings of the 7th International Electronic Conference on Medicinal\nChemistry, Basel, Switzerland1\u201330 Nov, 20212021.","DOI":"10.3390\/ECMC2021-11373"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","volume":"106","author":"Agatonovic-Kustrin S.","year":"2018","unstructured":"Agatonovic-Kustrin S.; Kettle C.; Morton D.W.; A molecular approach in drug development for Alzheimer\u2019s disease. Biomed Pharmacother  2018,106,553-565","journal-title":"Biomed Pharmacother"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.2174\/15680266113139990135","volume":"13","author":"Carreiras M.","year":"2013","unstructured":"Carreiras M.; Mendes E.; Perry M.; Francisco A.; Marco-Contelles J.; The multifactorial nature of Alzheimer\u2019s disease for developing potential therapeutics. Curr Top Med Chem  2013,13(15),1745-1770","journal-title":"Curr Top Med Chem"},{"key":"ref=34","first-page":"561","volume":"7","author":"Habibpour Gharacheh R.","year":"2019","unstructured":"Habibpour Gharacheh R.; Eslami M.; Amani P.; Bagheri Novir S.; Tacrine-flavonoid quercetin hybride as a MTDL ligand against alzheimer\u2019s disease with metal chelating and AChE, BChE, AChE-induced A\u03b2 aggregation inhibition properties: A computational study. Phys Chem Res  2019,7(3),561-579","journal-title":"Phys Chem Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"112751","DOI":"10.1016\/j.ejmech.2020.112751","volume":"207","author":"Jiang X.","year":"2020","unstructured":"Jiang X.; Zhou J.; Wang Y.; Chen L.; Duan Y.; Huang J.; Liu C.; Chen Y.; Liu W.; Sun H.; Feng F.; Qu W.; Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer\u2019s disease. Eur J Med Chem  2020,207,112751","journal-title":"Eur J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"106168","DOI":"10.1016\/j.bioorg.2022.106168","volume":"129","author":"Liu W.","year":"2022","unstructured":"Liu W.; Tian L.; Wu L.; Chen H.; Wang N.; Liu X.; Zhao C.; Wu Z.; Jiang X.; Wu Q.; Xu Z.; Liu W.; Zhao Q.; Discovery of novel \u03b2-carboline-1,2,3-triazole hybrids as AChE\/GSK-3\u03b2 dual inhibitors for Alzheimer\u2019s disease treatment. Bioorg Chem  2022,129,106168","journal-title":"Bioorg Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"113554","DOI":"10.1016\/j.ejmech.2021.113554","volume":"222","author":"Liu W.","year":"2021","unstructured":"Liu W.; Liu X.; Tian L.; Gao Y.; Liu W.; Chen H.; Jiang X.; Xu Z.; Ding H.; Zhao Q.; Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem  2021,222,113554","journal-title":"Eur J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","volume":"176","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; Xu S.; Zhu Z.; Xu J.; Multi-target design strategies for the improved treatment of Alzheimer\u2019s disease. Eur J Med Chem  2019,176,228-247","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.compbiolchem.2017.09.001","volume":"71","author":"Kumar A.","year":"2017","unstructured":"Kumar A.; Srivastava G.; Sharma A.; A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3\u03b2 as targets for Alzheimer\u2019s disease. Comput Biol Chem  2017,71,1-9","journal-title":"Comput Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"Seren\u00f3 L.","year":"2009","unstructured":"Seren\u00f3 L.; Coma M.; Rodr\u00edguez M.; S\u00e1nchez-Ferrer P.; S\u00e1nchez M.B.; Gich I.; Agull\u00f3 J.M.; P\u00e9rez M.; Avila J.; Guardia-Laguarta C.; Clarim\u00f3n J.; Lle\u00f3 A.; G\u00f3mez-Isla T.; A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis  2009,35(3),359-367","journal-title":"Neurobiol Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1586\/14737175.7.11.1527","volume":"7","author":"Avila J.","year":"2007","unstructured":"Avila J.; Hern\u00e1ndez F.; GSK-3 inhibitors for Alzheimer\u2019s disease. Expert Rev Neurother  2007,7(11),1527-1533","journal-title":"Expert Rev Neurother"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","volume":"33","author":"del Ser T.","year":"2012","unstructured":"del Ser T.; Steinwachs K.C.; Gertz H.J.; Andr\u00e9s M.V.; G\u00f3mez-Carrillo B.; Medina M.; Vericat J.A.; Redondo P.; Fleet D.; Le\u00f3n T.; Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: A pilot study. J Alzheimers Dis  2012,33(1),205-215","journal-title":"J Alzheimers Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/anie.201410456","volume":"54","author":"Prati F.","year":"2015","unstructured":"Prati F.; De Simone A.; Bisignano P.; Armirotti A.; Summa M.; Pizzirani D.; Scarpelli R.; Perez D.I.; Andrisano V.; Perez-Castillo A.; Monti B.; Massenzio F.; Polito L.; Racchi M.; Favia A.D.; Bottegoni G.; Martinez A.; Bolognesi M.L.; Cavalli A.; Multitarget drug discovery for Alzheimer\u2019s disease: Triazinones as BACE-1 and GSK-3\u03b2 inhibitors. Angew Chem Int Ed  2015,54(5),1578-1582","journal-title":"Angew Chem Int Ed"},{"key":"ref=44","first-page":"46","volume":"7","author":"Llorens-Mart\u00edn M.","year":"2014","unstructured":"Llorens-Mart\u00edn M.; Jurado J.; Hern\u00e1ndez F.; \u00c1vila J.; GSK-3\u03b2, a pivotal kinase in Alzheimer disease. Front Mol Neurosci  2014,7,46","journal-title":"Front Mol Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"45701","DOI":"10.1038\/srep45701","volume":"7","author":"Gameiro I.","year":"2017","unstructured":"Gameiro I.; Michalska P.; Tenti G.; Cores \u00c1.; Buendia I.; Rojo A.I.; Georgakopoulos N.D.; Hern\u00e1ndez-Guijo J.M.; Teresa Ramos M.; Wells G.; L\u00f3pez M.G.; Cuadrado A.; Men\u00e9ndez J.C.; Le\u00f3n R.; Discovery of the first dual GSK3\u03b2 inhibitor\/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer\u2019s disease. Sci Rep  2017,7(1),45701","journal-title":"Sci Rep"},{"year":"2019","author":"Venter J.","key":"ref=46","unstructured":"Venter J.; Design, synthesis and biological activity studies of 1-\naryl-3-(4-methoxybenzyl)ureas as proposed irreversible GSK-3 inhibitors\nin Alzheimer\u2019s disease therapeutic development.. Thesis,\nStellenbosch University,  2019"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"115766","DOI":"10.1016\/j.ejmech.2023.115766","volume":"260","author":"Abd El-Karim S.S.","year":"2023","unstructured":"Abd El-Karim S.S.; Anwar M.M.; Ahmed N.S.; Syam Y.M.; Elseginy S.A.; Aly H.F.; Younis E.A.; Khalil W.K.B.; Ahmed K.A.; Mohammed F.F.; Rizk M.; Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation. Eur J Med Chem  2023,260,115766","journal-title":"Eur J Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"ra110","DOI":"10.1126\/scisignal.aah7102","volume":"9","author":"Licht-Murava A.","year":"2016","unstructured":"Licht-Murava A.; Paz R.; Vaks L.; Avrahami L.; Plotkin B.; Eisenstein M.; Eldar-Finkelman H.; A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Sci Signal  2016,9(454),ra110-ra110","journal-title":"Sci Signal"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"Gannon M.","year":"2015","unstructured":"Gannon M.; Che P.; Chen Y.; Jiao K.; Roberson E.D.; Wang Q.; Noradrenergic dysfunction in Alzheimer\u2019s disease. Front Neurosci  2015,9,220","journal-title":"Front Neurosci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"Anand P.","year":"2013","unstructured":"Anand P.; Singh B.; A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch Pharm Res  2013,36(4),375-399","journal-title":"Arch Pharm Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1471-4159.2006.03764.x","volume":"97","author":"Ginsberg S.D.","year":"2006","unstructured":"Ginsberg S.D.; Che S.; Wuu J.; Counts S.E.; Mufson E.J.; Down regulation of trk but not p75 NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer\u2019s disease. J Neurochem  2006,97(2),475-487","journal-title":"J Neurochem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/0-387-23226-5_15","author":"Inestrosa N.C.","year":"2005","unstructured":"Inestrosa N.C.; Sagal J.P.; Colombres M.;  Alzheimer\u2019s Disease  2005,299-317","journal-title":"Alzheimer\u2019s Disease"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00002826-200405000-00011","volume":"27","author":"Lane R.M.","year":"2004","unstructured":"Lane R.M.; Kivipelto M.; Greig N.H.; Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol  2004,27(3),141-149","journal-title":"Clin Neuropharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000116655","volume":"31","author":"Mangoni A.","year":"1991","unstructured":"Mangoni A.; Grassi M.P.; Frattola L.; Piolti R.; Bassi S.; Motta A.; Marcone A.; Smirne S.; Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol  1991,31(2),100-107","journal-title":"Eur Neurol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","volume":"110","author":"Kennedy B.P.","year":"2003","unstructured":"Kennedy B.P.; Ziegler M.G.; Alford M.; Hansen L.A.; Thal L.J.; Masliah E.; Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease. J Neural Transm (Vienna)  2003,110(7),789-801","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1016\/j.bmc.2007.06.004","volume":"15","author":"G\u00f6khan-Kelek\u00e7i N.","year":"2007","unstructured":"G\u00f6khan-Kelek\u00e7i N.; Yabano\u011flu S.; K\u00fcpeli E.; Salg\u0131n U.; \u00d6zgen \u00d6.; U\u00e7ar G.; Ye\u015filada E.; Kendi E.; Ye\u015filada A.; Bilgin A.A.; A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem  2007,15(17),5775-5786","journal-title":"Bioorg Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuint.2010.10.013","volume":"58","author":"Guly\u00e1s B.","year":"2011","unstructured":"Guly\u00e1s B.; Pavlova E.; K\u00e1sa P.; Gulya K.; Bakota L.; V\u00e1rszegi S.; Keller \u00c9.; Horv\u00e1th M.C.; Nag S.; Hermecz I.; Magyar K.; Halldin C.; Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Int  2011,58(1),60-68","journal-title":"Neurochem Int"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/0024-3205(80)90025-9","volume":"27","author":"Adolfsson R.","year":"1980","unstructured":"Adolfsson R.; Gottfries C-G.; Oreland L.; Wiberg \u00c5.; Winblad B.; Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci  1980,27(12),1029-1034","journal-title":"Life Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"112787","DOI":"10.1016\/j.ejmech.2020.112787","volume":"206","author":"Manzoor S.","year":"2020","unstructured":"Manzoor S.; Hoda N.; A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer\u2019s disease agents: A review. Eur J Med Chem  2020,206,112787","journal-title":"Eur J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.18071\/isz.74.0379","volume":"74","author":"Bal\u00e1zs N.","year":"2021","unstructured":"Bal\u00e1zs N.; Bereczki D.; Kov\u00e1cs T.; Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias. Ideggyogy Sz  2021,74(11-12),379-387","journal-title":"Ideggyogy Sz"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1021\/ml200313p","volume":"3","author":"Rampa A.","year":"2012","unstructured":"Rampa A.; Bartolini M.; Bisi A.; Belluti F.; Gobbi S.; Andrisano V.; Ligresti A.; Di Marzo V.; The First Dual ChE\/FAAH Inhibitors: New Perspectives for Alzheimer\u2019s Disease? ACS Med Chem Lett  2012,3(3),182-186","journal-title":"ACS Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bioorg.2018.09.010","volume":"81","author":"He Q.","year":"2018","unstructured":"He Q.; Liu J.; Lan J.S.; Ding J.; Sun Y.; Fang Y.; Jiang N.; Yang Z.; Sun L.; Jin Y.; Xie S.S.; Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer\u2019s disease: Design, synthesis and biological evaluation. Bioorg Chem  2018,81,512-528","journal-title":"Bioorg Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2174\/15680266113139990120","volume":"13","author":"Y\u00e1\u00f1ez M.","year":"2013","unstructured":"Y\u00e1\u00f1ez M.; Vi\u00f1a D.; Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr Top Med Chem  2013,13(14),1692-1706","journal-title":"Curr Top Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.neuropharm.2016.06.013","volume":"109","author":"Liu W.","year":"2016","unstructured":"Liu W.; Lang M.; Youdim M.B.H.; Amit T.; Sun Y.; Zhang Z.; Wang Y.; Weinreb O.; Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer\u2019s disease. Neuropharmacology  2016,109,376-385","journal-title":"Neuropharmacology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1021\/acschemneuro.8b00357","volume":"10","author":"Xu Y.","year":"2019","unstructured":"Xu Y.; Zhang J.; Wang H.; Mao F.; Bao K.; Liu W.; Zhu J.; Li X.; Zhang H.; Li J.; Rational design of novel selective dual-target inhibitors of acetylcholinesterase and monoamine oxidase B as potential anti-Alzheimer\u2019s disease agents. ACS Chem Neurosci  2019,10(1),482-496","journal-title":"ACS Chem Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ejmech.2014.04.078","volume":"80","author":"Wang L.","year":"2014","unstructured":"Wang L.; Esteban G.; Ojima M.; Bautista-Aguilera O.M.; Inokuchi T.; Moraleda I.; Iriepa I.; Samadi A.; Youdim M.B.H.; Romero A.; Soriano E.; Herrero R.; Fern\u00e1ndez Fern\u00e1ndez A.P.; Mart\u00ednez-Murillo R.; Marco-Contelles J.; Unzeta M.; Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer\u2019s disease. Eur J Med Chem  2014,80,543-561","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1039\/C9MD00441F","volume":"11","author":"Wang X.B.","year":"2020","unstructured":"Wang X.B.; Yin F.C.; Huang M.; Jiang N.; Lan J.S.; Kong L.Y.; Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease. RSC Med Chem  2020,11(2),225-233","journal-title":"RSC Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2174\/1570159X18666201119153807","volume":"19","author":"Orhan I.E.","year":"2021","unstructured":"Orhan I.E.; Cholinesterase inhibitory potential of quercetin towards Alzheimer\u2019s disease - A promising natural molecule or fashion of the day? - A narrowed review. Curr Neuropharmacol  2021,19(12),2205-2213","journal-title":"Curr Neuropharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/pharmaceutics15082159","volume":"15","author":"Belinskaia D.A.","year":"2023","unstructured":"Belinskaia D.A.; Voronina P.A.; Krivorotov D.V.; Jenkins R.O.; Goncharov N.V.; Anticholinesterase and serotoninergic evaluation of benzimidazole\u2013carboxamides as potential multifunctional agents for the treatment of Alzheimer\u2019s disease. Pharmaceutics  2023,15(8),2159","journal-title":"Pharmaceutics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroscience.2017.06.034","volume":"370","author":"Kor\u00e1be\u010dn\u00fd J.","year":"2018","unstructured":"Kor\u00e1be\u010dn\u00fd J.; Nepovimov\u00e1 E.; Cik\u00e1nkov\u00e1 T.; \u0160pilovsk\u00e1 K.; Va\u0161kov\u00e1 L.; Mezeiov\u00e1 E.; Ku\u010da K.; Hroudov\u00e1 J.; Newly developed drugs for Alzheimer\u2019s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience  2018,370,191-206","journal-title":"Neuroscience"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"113492","DOI":"10.1016\/j.ejmech.2021.113492","volume":"221","author":"Ferreira J.P.S.","year":"2021","unstructured":"Ferreira J.P.S.; Albuquerque H.M.T.; Cardoso S.M.; Silva A.M.S.; Silva V.L.M.; Dual-target compounds for Alzheimer\u2019s disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Eur J Med Chem  2021,221,113492","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1021\/acs.jmedchem.7b00393","volume":"61","author":"Prati F.","year":"2018","unstructured":"Prati F.; Bottegoni G.; Bolognesi M.L.; Cavalli A.; BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer\u2019s disease. Miniperspective J Med Chem  2018,61(3),619-637","journal-title":"Miniperspective J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bioorg.2018.06.031","volume":"80","author":"Gabr M.T.","year":"2018","unstructured":"Gabr M.T.; Abdel-Raziq M.S.; Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors. Bioorg Chem  2018,80,245-252","journal-title":"Bioorg Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.bioorg.2020.103649","volume":"97","author":"Iraji A.","year":"2020","unstructured":"Iraji A.; Khoshneviszadeh M.; Firuzi O.; Khoshneviszadeh M.; Edraki N.; Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. Bioorg Chem  2020,97,103649","journal-title":"Bioorg Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1039\/D0FO00971G","volume":"11","author":"Yu Z.","year":"2020","unstructured":"Yu Z.; Ji H.; Shen J.; Kan R.; Zhao W.; Li J.; Ding L.; Liu J.; Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors. Food Funct  2020,11(7),6643-6651","journal-title":"Food Funct"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3390\/nu11112694","volume":"11","author":"Han J.","year":"2019","unstructured":"Han J.; Ji Y.; Youn K.; Lim G.; Lee J.; Kim D.H.; Jun M.; Baicalein as a potential inhibitor against BACE1 and AChE: Mechanistic comprehension through in vitro and computational approaches. Nutrients  2019,11(11),2694","journal-title":"Nutrients"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3390\/molecules25081846","volume":"25","author":"Ivanova L.","year":"2020","unstructured":"Ivanova L.; Karelson M.; Dobchev D.A.; Multitarget approach to drug candidates against Alzheimer\u2019s disease related to AChE, SERT, BACE1 and GSK3\u03b2 protein targets. Molecules  2020,25(8),1846","journal-title":"Molecules"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"9394","DOI":"10.1021\/acsomega.2c08061","volume":"8","author":"Waiker D.K.","year":"2023","unstructured":"Waiker D.K.; Verma A.; Saraf P.;; T A, G.; Krishnamurthy, S.; Chaurasia, R.N.; Shrivastava, S.K. Development and evaluation of some molecular hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio) as multifunctional agents to combat Alzheimer\u2019s disease. ACS Omega  2023,8(10),9394-9414","journal-title":"ACS Omega"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.3390\/molecules23123252","volume":"23","author":"Green K.D.","year":"2018","unstructured":"Green K.D.; Fosso M.Y.; Garneau-Tsodikova S.; Multifunctional donepezil analogues as cholinesterase and BACE1 inhibitors. Molecules  2018,23(12),3252","journal-title":"Molecules"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1080\/14756366.2022.2117315","volume":"37","author":"Gonz\u00e1lez-Naranjo P.","year":"2022","unstructured":"Gonz\u00e1lez-Naranjo P.; P\u00e9rez C.; Gonz\u00e1lez-S\u00e1nchez M.; Gironda-Mart\u00ednez A.; Ulzurrun E.; Bartolom\u00e9 F.; Rubio-Fern\u00e1ndez M.; Martin-Requero A.; Campillo N.E.; P\u00e1ez J.A.; Multitarget drugs as potential therapeutic agents for alzheimer\u2019s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors. J Enzyme Inhib Med Chem  2022,37(1),2348-2356","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e0269129","DOI":"10.1371\/journal.pone.0269129","volume":"17","author":"Garc\u00eda Mar\u00edn I.D.","year":"2022","unstructured":"Garc\u00eda Mar\u00edn I.D.; Camarillo L\u00f3pez R.H.; Mart\u00ednez O.A.; Padilla-Mart\u00ednez I.I.; Correa-Basurto J.; Rosales-Hern\u00e1ndez M.C.; New compounds from heterocyclic amines scaffold with multitarget inhibitory activity on A\u03b2 aggregation, AChE, and BACE1 in the Alzheimer disease. PLoS One  2022,17(6),e0269129","journal-title":"PLoS One"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"38855","DOI":"10.1007\/s11356-021-13320-y","volume":"28","author":"Mathew B.","year":"2021","unstructured":"Mathew B.; Oh J.M.; Baty R.S.; Batiha G.E.S.; Parambi D.G.T.; Gambacorta N.; Nicolotti O.; Kim H.; Piperazine-substituted chalcones: A new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders. Environ Sci Pollut Res Int  2021,28(29),38855-38866","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/ph12010041","volume":"12","author":"Maia M.A.","year":"2019","unstructured":"Maia M.A.; Sousa E.; BACE-1 and \u03b3-secretase as therapeutic targets for Alzheimer\u2019s disease. Pharmaceuticals (Basel)  2019,12(1),41","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","volume":"18","author":"Panza F.","year":"2018","unstructured":"Panza F.; Lozupone M.; Solfrizzi V.; Sardone R.; Piccininni C.; Dibello V.; Stallone R.; Giannelli G.; Bellomo A.; Greco A.; Daniele A.; Seripa D.; Logroscino G.; Imbimbo B.P.; BACE inhibitors in clinical development for the treatment of Alzheimer\u2019s disease. Expert Rev Neurother  2018,18(11),847-857","journal-title":"Expert Rev Neurother"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1515\/jbcpp-2016-0147","volume":"28","author":"Bui T.T.","year":"2017","unstructured":"Bui T.T.; Nguyen T.H.; Natural product for the treatment of Alzheimer\u2019s disease. J Basic Clin Physiol Pharmacol  2017,28(5),413-423","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.2174\/0929867326666190618113613","volume":"27","author":"Panda S.S.","year":"2020","unstructured":"Panda S.S.; Jhanji N.; Natural products as potential anti-Alzheimer agents. Curr Med Chem  2020,27(35),5887-5917","journal-title":"Curr Med Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0169-328X(03)00233-X","volume":"116","author":"Preece P.","year":"2003","unstructured":"Preece P.; Virley D.J.; Costandi M.; Coombes R.; Moss S.J.; Mudge A.W.; Jazin E.; Cairns N.J.; \u03b2-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer\u2019s disease. Brain Res Mol Brain Res  2003,116(1-2),155-158","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2174\/1568026618666180112161406","volume":"17","author":"Rampa A.","year":"2018","unstructured":"Rampa A.; Gobbi S.; Concetta Di Martino R.M.; Belluti F.; Bisi A.; Dual BACE-1\/GSK-3\u03b2 inhibitors to combat Alzheimer\u2019s disease: A focused review. Curr Top Med Chem  2018,17(31),3361-3369","journal-title":"Curr Top Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jsps.2021.01.007","volume":"29","author":"G\u00fcrb\u00fcz P.","year":"2021","unstructured":"G\u00fcrb\u00fcz P.; Dokumac\u0131 A.H.; G\u00fcnd\u00fcz M.G.; Perez C.; G\u00f6ger F.; Paksoy M.Y.; Yerer M.B.; \u00d6m\u00fcr Demirezer L.; In vitro biological activity of Salvia fruticosa Mill. infusion against amyloid \u03b2-peptide-induced toxicity and inhibition of GSK-3\u03b2, CK-1\u03b4, and BACE-1 enzymes relevant to Alzheimer\u2019s disease. Saudi Pharm J  2021,29(3),236-243","journal-title":"Saudi Pharm J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1007\/s11696-022-02421-8","volume":"76","author":"Bajad N.G.","year":"2022","unstructured":"Bajad N.G.; Swetha R.; Singh R.; Ganeshpurkar A.; Gutti G.; Singh R.B.; Kumar A.; Singh S.K.; Combined structure and ligand-based design of dual BACE-1\/GSK-3\u03b2 inhibitors for Alzheimer\u2019s disease. Chem Zvesti  2022,76(12),7507-7524","journal-title":"Chem Zvesti"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acs.jmedchem.5b00894","volume":"59","author":"Di Martino R.M.C.","year":"2016","unstructured":"Di Martino R.M.C.; De Simone A.; Andrisano V.; Bisignano P.; Bisi A.; Gobbi S.; Rampa A.; Fato R.; Bergamini C.; Perez D.I.; Martinez A.; Bottegoni G.; Cavalli A.; Belluti F.; Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3\u03b2 Inhibitors. J Med Chem  2016,59(2),531-544","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00894-017-3396-7","volume":"23","author":"Kumar A.","year":"2017","unstructured":"Kumar A.; Srivastava G.; Srivastava S.; Verma S.; Negi A.S.; Sharma A.; Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3\u03b2: Molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer\u2019s disease. J Mol Model  2017,23(8),239","journal-title":"J Mol Model"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/6873874","volume":"2022","author":"Chakraborty B.","year":"2022","unstructured":"Chakraborty B.; Mukerjee N.; Maitra S.; Zehravi M.; Mukherjee D.; Ghosh A.; Massoud E.E.S.; Rahman M.H.; Therapeutic potential of different natural products for the treatment of Alzheimer\u2019s Disease. Oxid Med Cell Longev  2022,2022(1),1-18","journal-title":"Oxid Med Cell Longev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells10061309","volume":"10","author":"Chen X.","year":"2021","unstructured":"Chen X.; Drew J.; Berney W.; Lei W.; Neuroprotective natural products for Alzheimer\u2019s disease. Cells  2021,10(6),1309","journal-title":"Cells"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"648636","DOI":"10.3389\/fphar.2021.648636","volume":"12","author":"Long H.Z.","year":"2021","unstructured":"Long H.Z.; Cheng Y.; Zhou Z.W.; Luo H.Y.; Wen D.D.; Gao L.C.; PI3K\/AKT signal pathway: A target of natural products in the prevention and treatment of Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Pharmacol  2021,12,648636","journal-title":"Front Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"111609","DOI":"10.1016\/j.biopha.2021.111609","volume":"139","author":"Ahmed S.","year":"2021","unstructured":"Ahmed S.; Khan S.T.; Zargaham M.K.; Khan A.U.; Khan S.; Hussain A.; Uddin J.; Khan A.; Al-Harrasi A.; Potential therapeutic natural products against Alzheimer\u2019s disease with reference of acetylcholinesterase. Biomed Pharmacother  2021,139,111609","journal-title":"Biomed Pharmacother"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fphar.2018.00548","volume":"9","author":"Shal B.","year":"2018","unstructured":"Shal B.; Ding W.; Ali H.; Kim Y.S.; Khan S.; Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer\u2019s disease. Front Pharmacol  2018,9,548","journal-title":"Front Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e2000442","DOI":"10.1002\/cbdv.202000442","volume":"17","author":"Yang A.","year":"2020","unstructured":"Yang A.; Yu Q.; Ju H.; Song L.; Kou X.; Shen R.; Design, Synthesis and biological evaluation of xanthone derivatives for possible treatment of Alzheimer\u2019s disease based on multi\u2010target strategy. Chem Biodivers  2020,17(10),e2000442","journal-title":"Chem Biodivers"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2174\/1568026619666181120143050","volume":"18","author":"Malik N.","year":"2019","unstructured":"Malik N.; Dhiman P.; Sobarzo-Sanchez E.; Khatkar A.; Flavonoids and anthranquinones as xanthine oxidase and monoamine oxidase inhibitors: A new approach towards inflammation and oxidative stress. Curr Top Med Chem  2019,18(25),2154-2164","journal-title":"Curr Top Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ejmech.2018.05.004","volume":"152","author":"Jalili-Baleh L.","year":"2018","unstructured":"Jalili-Baleh L.; Babaei E.; Abdpour S.; Nasir Abbas Bukhari S.; Foroumadi A.; Ramazani A.; Sharifzadeh M.; Abdollahi M.; Khoobi M.; A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer\u2019s disease. Eur J Med Chem  2018,152,570-589","journal-title":"Eur J Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.3390\/ijms232314835","volume":"23","author":"Calderaro A.","year":"2022","unstructured":"Calderaro A.; Patan\u00e8 G.T.; Tellone E.; Barreca D.; Ficarra S.; Misiti F.; Lagan\u00e0 G.; The neuroprotective potentiality of flavonoids on Alzheimer\u2019s disease. Int J Mol Sci  2022,23(23),14835","journal-title":"Int J Mol Sci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/JAD-210735","volume":"84","author":"Wang Q.","year":"2021","unstructured":"Wang Q.; Dong X.; Zhang R.; Zhao C.; Flavonoids with potential anti-amyloidogenic effects as therapeutic drugs for treating Alzheimer\u2019s disease. J Alzheimers Dis  2021,84(2),505-533","journal-title":"J Alzheimers Dis"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"10020","DOI":"10.3390\/ijms231710020","volume":"23","author":"Li J.","year":"2022","unstructured":"Li J.; Sun M.; Cui X.; Li C.; Protective effects of flavonoids against Alzheimer\u2019s disease: Pathological hypothesis, potential targets, and structure\u2013activity relationship. Int J Mol Sci  2022,23(17),10020","journal-title":"Int J Mol Sci"},{"author":"Wong K.W.","key":"ref=104","doi-asserted-by":"publisher","unstructured":"Wong K.W.; Mah S.H.;","DOI":"10.1016\/B978-0-12-819485-0.00003-7"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fnagi.2019.00155","volume":"11","author":"Ayaz M.","year":"2019","unstructured":"Ayaz M.; Sadiq A.; Junaid M.; Ullah F.; Ovais M.; Ullah I.; Ahmed J.; Shahid M.; Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front Aging Neurosci  2019,11,155","journal-title":"Front Aging Neurosci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.biopha.2017.06.010","volume":"93","author":"Bakhtiari M.","year":"2017","unstructured":"Bakhtiari M.; Panahi Y.; Ameli J.; Darvishi B.; Protective effects of flavonoids against Alzheimer\u2019s disease-related neural dysfunctions. Biomed Pharmacother  2017,93,218-229","journal-title":"Biomed Pharmacother"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.4103\/1673-5374.373680","volume":"18","author":"Zhang Q.","year":"2023","unstructured":"Zhang Q.; Yan Y.; The role of natural flavonoids on neuroinflammation as a therapeutic target for Alzheimer\u2019s disease: A narrative review. Neural Regen Res  2023,18(12),2582-2591","journal-title":"Neural Regen Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.biopha.2018.03.007","volume":"101","author":"Khan H.;","year":"2018","unstructured":"Khan H.;; Marya, ; Amin, S.; Kamal, M.A.; Patel, S. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. Biomed Pharmacother  2018,101,860-870","journal-title":"Biomed Pharmacother"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.3390\/molecules27207092","volume":"27","author":"Hung N.H.","year":"2022","unstructured":"Hung N.H.; Quan P.M.; Satyal P.; Dai D.N.; Hoa V.V.; Huy N.G.; Giang L.D.; Ha N.T.; Huong L.T.; Hien V.T.; Setzer W.N.; Acetylcholinesterase inhibitory activities of essential oils from vietnamese traditional medicinal plants. Molecules  2022,27(20),7092","journal-title":"Molecules"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"105486","DOI":"10.1016\/j.neuint.2023.105486","volume":"163","author":"Punmiya A.","year":"2023","unstructured":"Punmiya A.; Prabhu A.; Structural fingerprinting of pleiotropic flavonoids for multifaceted Alzheimer\u2019s disease. Neurochem Int  2023,163,105486","journal-title":"Neurochem Int"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.4155\/fmc-2017-0086","volume":"9","author":"Cruz M.I.","year":"2017","unstructured":"Cruz M.I.; Cidade H.; Pinto M.; Dual\/multitargeted xanthone derivatives for Alzheimer\u2019s disease: where do we stand? Future Med Chem  2017,9(14),1611-1630","journal-title":"Future Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3389\/fphar.2018.01192","volume":"9","author":"Santos T.C.","year":"2018","unstructured":"Santos T.C.; Gomes T.M.; Pinto B.A.S.; Camara A.L.; Paes A.M.A.; Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer\u2019s disease therapy. Front Pharmacol  2018,9,1192","journal-title":"Front Pharmacol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.3390\/molecules26185582","volume":"26","author":"Tamfu A.N.","year":"2021","unstructured":"Tamfu A.N.; Kucukaydin S.; Yeskaliyeva B.; Ozturk M.; Dinica R.M.; Non-alkaloid cholinesterase inhibitory compounds from natural sources. Molecules  2021,26(18),5582","journal-title":"Molecules"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/cns.12971","volume":"24","author":"Jabir N.R.","year":"2018","unstructured":"Jabir N.R.; Khan F.R.; Tabrez S.; Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer\u2019s disease. CNS Neurosci Ther  2018,24(9),753-762","journal-title":"CNS Neurosci Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.2174\/1389557521666210212152514","volume":"21","author":"Vanessa V.V.","year":"2021","unstructured":"Vanessa V.V.; Mah S.H.; Xanthone: Potential acetylcholinesterase inhibitor for Alzheimer\u2019s disease treatment. Mini Rev Med Chem  2021,21(17),2507-2529","journal-title":"Mini Rev Med Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.3390\/ijms22179290","volume":"22","author":"Walczak-Nowicka \u0141.J.","year":"2021","unstructured":"Walczak-Nowicka \u0141.J.; Herbet M.; Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Int J Mol Sci  2021,22(17),9290","journal-title":"Int J Mol Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/molecules23092344","volume":"23","author":"Prasasty V.","year":"2018","unstructured":"Prasasty V.; Radifar M.; Istyastono E.; Natural peptides in drug discovery targeting acetylcholinesterase. Molecules  2018,23(9),2344","journal-title":"Molecules"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ddr.21587","volume":"81","author":"Patil P.","year":"2020","unstructured":"Patil P.; Thakur A.; Sharma A.; Flora S.J.S.; Natural products and their derivatives as multifunctional ligands against Alzheimer\u2019s disease. Drug Dev Res  2020,81(2),165-183","journal-title":"Drug Dev Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.2174\/1875533XMTA4aNzUBx","volume":"28","author":"Mir R.H.","year":"2021","unstructured":"Mir R.H.; Shah A.J.; Mohi-Ud-Din R.; Pottoo F.H.; Dar M.A.; Jachak S.M.; Masoodi M.H.; Natural anti-inflammatory compounds as drug candidates in Alzheimer\u2019s disease. Curr Med Chem  2021,28(23),4799-4825","journal-title":"Curr Med Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1568026619666190201153257","volume":"19","author":"Wu X.","year":"2019","unstructured":"Wu X.; Cai H.; Pan L.; Cui G.; Qin F.; Li Y.; Cai Z.; Small molecule natural products and Alzheimer\u2019s disease. Curr Top Med Chem  2019,19(3),187-204","journal-title":"Curr Top Med Chem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.3390\/app11115044","volume":"11","author":"Ribaudo G.","year":"2021","unstructured":"Ribaudo G.; Memo M.; Gianoncelli A.; Multi-target natural and nature-inspired compounds against neurodegeneration: A focus on dual cholinesterase and phosphodiesterase inhibitors. Appl Sci (Basel)  2021,11(11),5044","journal-title":"Appl Sci (Basel)"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5044.2021","DOI":"10.3390\/app11115044","volume":"11","author":"Varshney H.","unstructured":"Varshney H.; Siddique Y.H.;  Multi-target natural and nature-inspired compounds against neurodegeneration: A focus on dual cholinesterase and phosphodiesterase inhibitors Appl Sci,  ,11(11),5044.2021","journal-title":"Multi-target natural and nature-inspired compounds against neurodegeneration: A focus on dual cholinesterase and phosphodiesterase inhibitors Appl Sci,"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-444-64185-4.00001-0","volume":"62","author":"Takahashi J.A.","year":"2019","unstructured":"Takahashi J.A.; Sande D.; da Silva Lima G.; Moura M.A.F.; Lima M.T.N.S.;  In: Studies in Natural Products Chemistry; Elsevier  2019,62,1-39","journal-title":"In: Studies in Natural Products Chemistry; Elsevier"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1007\/s00253-020-10560-9","volume":"104","author":"Zaki A.G.","year":"2020","unstructured":"Zaki A.G.; El-Sayed E.S.R.; Abd Elkodous M.; El-Sayyad G.S.; Microbial acetylcholinesterase inhibitors for Alzheimer\u2019s therapy: Recent trends on extraction, detection, irradiation-assisted production improvement and nano-structured drug delivery. Appl Microbiol Biotechnol  2020,104(11),4717-4735","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"173974","DOI":"10.1016\/j.ejphar.2021.173974","volume":"898","author":"Noori T.","year":"2021","unstructured":"Noori T.; Dehpour A.R.; Sureda A.; Sobarzo-Sanchez E.; Shirooie S.; Role of natural products for the treatment of Alzheimer\u2019s disease. Eur J Pharmacol  2021,898,173974","journal-title":"Eur J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1871527320666210811160007","volume":"21","author":"Ahmad S.S.","year":"2022","unstructured":"Ahmad S.S.; Younis K.; Philippe J.; Aschner M.; Khan H.; Strategic approaches to target the enzymes using natural compounds for the management of Alzheimer\u2019s disease: A review. CNS Neurol Disord Drug Targets  2022,21(7),610-620","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31083\/j.jin.2019.03.1105","volume":"18","author":"Zhu Y.","year":"2019","unstructured":"Zhu Y.; Peng L.; Hu J.; Chen Y.; Chen F.; Current anti-Alzheimer\u2019s disease effect of natural products and their principal targets. J Integr Neurosci  2019,18(3),327-339","journal-title":"J Integr Neurosci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.3390\/ijms24054399","volume":"24","author":"Vrabec R.","year":"2023","unstructured":"Vrabec R.; Blunden G.; Cahl\u00edkov\u00e1 L.; Natural alkaloids as multi-target compounds towards factors implicated in Alzheimer\u2019s disease. Int J Mol Sci  2023,24(5),4399","journal-title":"Int J Mol Sci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.3390\/ijms21103438","volume":"21","author":"Moss D.E.","year":"2020","unstructured":"Moss D.E.; Improving anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer\u2019s disease: Are irreversible inhibitors the future? Int J Mol Sci  2020,21(10),3438","journal-title":"Int J Mol Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"123","DOI":"10.48175\/IJARSCT-733","volume":"1","author":"Sabu Sneha","year":"2021","unstructured":"Sabu Sneha; Jothilin Subitsha; A. Research advantages in marine microbial acetylcholinesterase inhibitors against Alzheimer\u2019s disease: An overview. Int J Adv Res Sci Commun Technol  2021,1(2),123-130","journal-title":"Int J Adv Res Sci Commun Technol"},{"key":"ref=131","first-page":"189","volume":"14","author":"Zhang C.","year":"2012","unstructured":"Zhang C.; Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer\u2019s disease. Discov Med  2012,14(76),189-197","journal-title":"Discov Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00894-021-04679-3","volume":"27","author":"Kushwaha P.","year":"2021","unstructured":"Kushwaha P.; Singh V.; Somvanshi P.; Bhardwaj T.; Barreto G.E.; Ashraf G.M.; Mishra B.N.; Chundawat R.S.; Haque S.; Identification of new BACE1 inhibitors for treating Alzheimer\u2019s disease. J Mol Model  2021,27(2),58","journal-title":"J Mol Model"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.3390\/molecules27134175","volume":"27","author":"Wang S.","year":"2022","unstructured":"Wang S.; Kong X.; Chen Z.; Wang G.; Zhang J.; Wang J.; role of natural compounds and target enzymes in the treatment of Alzheimer\u2019s disease. Molecules  2022,27(13),4175","journal-title":"Molecules"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"111609","DOI":"10.1016\/j.biopha.2021.111609","volume":"139","author":"Ahmed S.","year":"2021","unstructured":"Ahmed S.; Khan S.T.; Zargaham M.K.; Khan A.U.; Khan S.; Hussain A.; Uddin J.; Khan A.; Al-Harrasi A.; Potential therapeutic natural products against Alzheimer\u2019s disease with Reference of Acetylcholinesterase. Biomed Pharmacother  2021,139,111609","journal-title":"Biomed Pharmacother"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1021\/acschemneuro.0c00579","volume":"11","author":"Das S.","year":"2020","unstructured":"Das S.; Sengupta S.; Chakraborty S.; Scope of \u03b2-secretase (bace1)-targeted therapy in alzheimer\u2019s disease: Emphasizing the flavonoid based natural scaffold for bace1 inhibition. ACS Chem Neurosci  2020,11(21),3510-3522","journal-title":"ACS Chem Neurosci"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1055\/a-1019-9819","volume":"85","author":"Naushad M.","year":"2019","unstructured":"Naushad M.; Durairajan S.S.K.; Bera A.K.; Senapati S.; Li M.; Natural compounds with anti-BACE1 activity as promising therapeutic drugs for treating Alzheimer\u02bcs disease. Planta Med  2019,85(17),1316-1325","journal-title":"Planta Med"},{"key":"ref=137","first-page":"311","volume":"13","author":"Ahmad S.S.","year":"2017","unstructured":"Ahmad S.S.; Akhtar S.; Danish Rizvi, S.M.; Kamal, M.A.; Sayeed, U.; Khan, M.K.A.; Siddiqui, M.H.; Arif, J.M. Screening and elucidation of selected natural compounds for anti-Alzheimer\u2019s potential targeting BACE-1 enzyme: A case computational study. Curr Computeraided Drug Des  2017,13(4),311-318","journal-title":"Curr Computeraided Drug Des"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"113576","DOI":"10.1016\/j.biopha.2022.113576","volume":"154","author":"Dai R.","year":"2022","unstructured":"Dai R.; Sun Y.; Su R.; Gao H.; Anti-Alzheimer\u2019s disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes. Biomed Pharmacother  2022,154,113576","journal-title":"Biomed Pharmacother"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.bbrc.2013.12.088","volume":"443","author":"Dhanjal J.K.","year":"2014","unstructured":"Dhanjal J.K.; Goyal S.; Sharma S.; Hamid R.; Grover A.; Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer\u2019s plaque pathology. Biochem Biophys Res Commun  2014,443(3),1054-1059","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"153244","DOI":"10.1016\/j.phymed.2020.153244","volume":"75","author":"Wang H.Q.","year":"2020","unstructured":"Wang H.Q.; Liu M.; Wang L.; Lan F.; Zhang Y.H.; Xia J.E.; Xu Z.D.; Zhang H.; Identification of a novel BACE1 inhibitor, timosaponin A-III, for treatment of Alzheimer\u2019s disease by a cell extraction and chemogenomics target knowledgebase-guided method. Phytomedicine  Advance online publication2020,75,153244","journal-title":"Phytomedicine"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/1389557523666221118113923","volume":"23","author":"Prado P.C.","year":"2023","unstructured":"Prado P.C.; Lima J.A.; Hamerski L.; Renn\u00f3 M.N.; Natural products with BACE1 and GSK3\u03b2 inhibitory activity. Mini Rev Med Chem  2023,23(7),881-895","journal-title":"Mini Rev Med Chem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/ijms22052341","volume":"22","author":"Lee J.H.","year":"2021","unstructured":"Lee J.H.; Ahn N.H.; Choi S.B.; Kwon Y.; Yang S.H.; Natural products targeting amyloid beta in Alzheimer\u2019s disease. Int J Mol Sci  2021,22(5),2341","journal-title":"Int J Mol Sci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.ijbiomac.2020.09.232","volume":"165","author":"Das S.","year":"2020","unstructured":"Das S.; Majumder T.; Sarkar A.; Mukherjee P.; Basu S.; Flavonoids\nas BACE1 inhibitors: QSAR modelling, screening and in\nvitro evaluation. Int. J. Biol. Macromol.,  2020,165(Pt A),1323-1330"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/138920207783769512","volume":"8","author":"Vassar R.","year":"2007","unstructured":"Vassar R.; Cole S.; The basic biology of BACE1: A key therapeutic target for Alzheimer\u2019s disease. Curr Genomics  2007,8(8),509-530","journal-title":"Curr Genomics"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1039\/b909989c","volume":"27","author":"La Clair J.J.","year":"2010","unstructured":"La Clair J.J.; Natural product mode of action (MOA) studies: A link between natural and synthetic worlds. Nat Prod Rep  2010,27(7),969-995","journal-title":"Nat Prod Rep"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cca.2012.08.013","volume":"414","author":"Sathya M.","year":"2012","unstructured":"Sathya M.; Premkumar P.; Karthick C.; Moorthi P.; Jayachandran K.S.; Anusuyadevi M.; BACE1 in Alzheimer\u2019s disease. Clin Chim Acta  2012,414,171-178","journal-title":"Clin Chim Acta"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/med.21622","volume":"40","author":"Moussa-Pacha N.M.","year":"2020","unstructured":"Moussa-Pacha N.M.; Abdin S.M.; Omar H.A.; Alniss H.; Al-Tel T.H.; BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease. Med Res Rev  2020,40(1),339-384","journal-title":"Med Res Rev"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.09.038","author":"Willbold D.","year":"2019","unstructured":"Willbold D.; Kutzsche J.; Schemmert S.; Willuweit A.; J\u00fcrgens D.; P4\u2010672: Exploring a potentially different or additional moa for the clinical stage compound PRI\u2010002. Alzheimers Dement., 15(7S_Part_30), 1589-P1589 2019"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"105070","DOI":"10.1016\/j.bioorg.2021.105070","volume":"114","author":"Zhang C.","year":"2021","unstructured":"Zhang C.; Lv Y.; Bai R.; Xie Y.; Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer\u2019s disease. Bioorg Chem  2021,114,105070","journal-title":"Bioorg Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"239","DOI":"10.18596\/jotcsa.823874","volume":"8","author":"Ege T.","year":"2021","unstructured":"Ege T.; \u015eeli\u0307men H.; Monoamine Oxidase Inhibitory Effects of Medicinal Plants in Management of Alzheimer\u2019s Disease. J Turk Chem Soc A: Chem  2021,8(1),239-248","journal-title":"J Turk Chem Soc A: Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"13953","DOI":"10.1038\/s41598-021-93458-4","volume":"11","author":"Oh J.M.","year":"2021","unstructured":"Oh J.M.; Jang H.J.; Kang M.G.; Song S.; Kim D.Y.; Kim J.H.; Noh J.I.; Park J.E.; Park D.; Yee S.T.; Kim H.; Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii. Sci Rep  2021,11(1),13953","journal-title":"Sci Rep"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.2174\/1875533XMTEzjOTQcw","volume":"28","author":"\u00d6zdemir Z.","year":"2021","unstructured":"\u00d6zdemir Z.; Alag\u00f6z M.A.; Bah\u00e7ecio\u011flu \u00d6.F.; G\u00f6k S.; Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Curr Med Chem  2021,28(29),6045-6065","journal-title":"Curr Med Chem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1016\/j.ejmech.2011.05.048","volume":"46","author":"Samadi A.","year":"2011","unstructured":"Samadi A.; Chioua M.; Bolea I.; de los R\u00edos C.; Iriepa I.; Moraleda I.; Bastida A.; Esteban G.; Unzeta M.; G\u00e1lvez E.; Marco-Contelles J.; Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease. Eur J Med Chem  2011,46(9),4665-4668","journal-title":"Eur J Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1871524919666190619090852","volume":"19","author":"Engelbrecht I.","unstructured":"Engelbrecht I.; Petzer J.P.; Petzer A.; Evaluation of selected natural compounds as dual inhibitors of catechol-O-methyltransferase and monoamine oxidase. Cent Nerv Syst Agents Med Chem,  ,19(2),133-145.2019","journal-title":"Cent Nerv Syst Agents Med Chem,"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13065-020-0661-0","volume":"14","author":"Dhiman P.","year":"2020","unstructured":"Dhiman P.; Malik N.; Khatkar A.; Natural based piperine derivatives as potent monoamine oxidase inhibitors: An in silico ADMET analysis and molecular docking studies. BMC Chem  2020,14(1),12","journal-title":"BMC Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13065-018-0497-z","volume":"12","author":"Yusufzai S.K.","year":"2018","unstructured":"Yusufzai S.K.; Khan M.S.; Sulaiman O.; Osman H.; Lamjin D.N.; Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A\/B and \u03b2-amyloid inhibitors for Alzheimer\u2019s disease. Chem Cent J  2018,12(1),128","journal-title":"Chem Cent J"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"862","DOI":"10.2174\/1386207323666200127145246","volume":"23","author":"Gulcan H.O.","year":"2020","unstructured":"Gulcan H.O.; Orhan I.E.; A recent look into natural products that have potential to inhibit cholinesterases and monoamine oxidase B: Update for 2010-2019. Comb Chem High Throughput Screen  2020,23(9),862-876","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1900177","DOI":"10.1002\/ardp.201900177","volume":"352","author":"Mathew B.","year":"2019","unstructured":"Mathew B.; Parambi D.G.T.; Mathew G.E.; Uddin M.S.; Inasu S.T.; Kim H.; Marathakam A.; Unnikrishnan M.K.; Carradori S.; Emerging therapeutic potentials of dual\u2010acting MAO and AChE inhibitors in Alzheimer\u2019s and Parkinson\u2019s diseases. Arch Pharm (Weinheim)  2019,352(11),1900177","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"e13571","DOI":"10.1111\/jfbc.13571","volume":"45","author":"Chowdhury S.","year":"2021","unstructured":"Chowdhury S.; Kumar S.; Inhibition of BACE1, MAO\u2010B, cholinesterase enzymes, and anti\u2010amyloidogenic potential of selected natural phytoconstituents: Multi\u2010target\u2010directed ligand approach. J Food Biochem  2021,45(1),e13571","journal-title":"J Food Biochem"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/B978-0-12-809593-5.00003-3","author":"Tundis R.","year":"2018","unstructured":"Tundis R.; Loizzo M.R.; Nabavi S.M.; Orhan I.E.; Skalicka-Wo\u017aniak K.; D\u2019Onofrio G.; Aiello F.;  In: Discovery and Development of Neuroprotective Agents from Natural Products  2018,63-102","journal-title":"In: Discovery and Development of Neuroprotective Agents from Natural Products"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"Panza F.","year":"2019","unstructured":"Panza F.; Lozupone M.; Logroscino G.; Imbimbo B.P.; A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol  2019,15(2),73-88","journal-title":"Nat Rev Neurol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1567205016666190321163438","volume":"16","author":"Pinheiro L.","year":"2019","unstructured":"Pinheiro L.; Faustino C.; Therapeutic strategies targeting amyloid-\u03b2 in Alzheimer\u2019s disease. Curr Alzheimer Res  2019,16(5),418-452","journal-title":"Curr Alzheimer Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Zhang Y.","year":"2023","unstructured":"Zhang Y.; Chen H.; Li R.; Sterling K.; Song W.; Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future. Signal Transduct Target Ther  2023,8(1),248","journal-title":"Signal Transduct Target Ther"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/11536110-000000000-00000","volume":"27","author":"Gong C.X.","year":"2010","unstructured":"Gong C.X.; Grundke-Iqbal I.; Iqbal K.; Targeting tau protein in Alzheimer\u2019s disease. Drugs Aging  2010,27(5),351-365","journal-title":"Drugs Aging"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"Congdon E.E.","year":"2018","unstructured":"Congdon E.E.; Sigurdsson E.M.; Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol  2018,14(7),399-415","journal-title":"Nat Rev Neurol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/S0140-6736(16)32107-9","volume":"388","author":"Rafii M.S.","year":"2016","unstructured":"Rafii M.S.; Targeting tau protein in Alzheimer\u2019s disease. Lancet  2016,388(10062),2842-2844","journal-title":"Lancet"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s10787-021-00889-6","volume":"29","author":"Dhapola R.","year":"2021","unstructured":"Dhapola R.; Hota S.S.; Sarma P.; Bhattacharyya A.; Medhi B.; Reddy D.H.; Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology  2021,29(6),1669-1681","journal-title":"Inflammopharmacology"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"Thakur S.","year":"2023","unstructured":"Thakur S.; Dhapola R.; Sarma P.; Medhi B.; Reddy D.H.; Neuroinflammation in Alzheimer\u2019s disease: Current progress in molecular signaling and therapeutics. Inflammation  2023,46(1),1-17","journal-title":"Inflammation"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"110112","DOI":"10.1016\/j.pnpbp.2020.110112","volume":"106","author":"Goyal D.","year":"2021","unstructured":"Goyal D.; Ali S.A.; Singh R.K.; Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry  2021,106,110112","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/brain\/awab375","volume":"145","author":"Khan A.F.","year":"2022","unstructured":"Khan A.F.; Adewale Q.; Baumeister T.R.; Carbonell F.; Zilles K.; Palomero-Gallagher N.; Iturria-Medina Y.; Personalized brain models identify neurotransmitter receptor changes in Alzheimer\u2019s disease. Brain  2022,145(5),1785-1804","journal-title":"Brain"},{"key":"ref=171","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04333-y","author":"Akyuz E.","year":"2024","unstructured":"Akyuz E.; Arulsamy A.; Aslan F.S.; Saris\u00f6zen B.; Guney B.; Hekimoglu A.; Yilmaz B.N.; Retinasamy T.; Shaikh M.F.; An expanded narrative review of neurotransmitters on Alzheimer\u2019s disease: The role of therapeutic interventions on neurotransmission. Mol Neurobiol  2024","journal-title":"Mol Neurobiol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3233\/JAD-161118","volume":"57","author":"Kandimalla R.","year":"2017","unstructured":"Kandimalla R.; Reddy P.H.; Therapeutics of neurotransmitters in Alzheimer\u2019s disease. J Alzheimers Dis  2017,57(4),1049-1069","journal-title":"J Alzheimers Dis"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1192\/bjp.157.3.327","volume":"157","author":"Bowen D.M.","year":"1990","unstructured":"Bowen D.M.; Treatment of Alzheimer\u2019s disease. Molecular pathology versus neurotransmitter-based therapy. Br J Psychiatry  1990,157(3),327-330","journal-title":"Br J Psychiatry"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/pharmaceutics13091397","volume":"13","author":"Riscado M.","year":"2021","unstructured":"Riscado M.; Baptista B.; Sousa F.; New RNA-based breakthroughs in Alzheimer\u2019s disease diagnosis and therapeutics. Pharmaceutics  2021,13(9),1397","journal-title":"Pharmaceutics"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1021\/acs.molpharmaceut.1c00611","volume":"18","author":"Arora S.","year":"2021","unstructured":"Arora S.; Sharma D.; Layek B.; Singh J.; A review of brain-targeted nonviral gene-based therapies for the treatment of Alzheimer\u2019s disease. Mol Pharm  2021,18(12),4237-4255","journal-title":"Mol Pharm"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/bfgp\/elm005","volume":"6","author":"Jagannath A.","year":"2007","unstructured":"Jagannath A.; Wood M.; RNA interference based gene therapy for neurological disease. Brief Funct Genomics Proteomics  2007,6(1),40-49","journal-title":"Brief Funct Genomics Proteomics"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/1568026615666150813144003","volume":"16","author":"Li L.","year":"2015","unstructured":"Li L.; Zhang L.; Yang C.; Multi-target strategy and experimental studies of traditional Chinese medicine for Alzheimer\u2019s disease therapy. Curr Top Med Chem  2015,16(5),537-548","journal-title":"Curr Top Med Chem"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2174\/0929867328666210512005508","volume":"29","author":"Kumar R.","year":"2022","unstructured":"Kumar R.; Kumar V.; Kumar B.; Thakur A.; Dwivedi A.R.; Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer\u2019s disease. Curr Med Chem  2022,29(10),1757-1803","journal-title":"Curr Med Chem"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.ejmech.2011.07.004","volume":"46","author":"Rizzo S.","year":"2011","unstructured":"Rizzo S.; Bisi A.; Bartolini M.; Mancini F.; Belluti F.; Gobbi S.; Andrisano V.; Rampa A.; Multi-target strategy to address Alzheimer\u2019s disease: Design, synthesis and biological evaluation of new tacrine-based dimers. Eur J Med Chem  2011,46(9),4336-4343","journal-title":"Eur J Med Chem"}],"container-title":["Central Nervous System Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249333381241012073557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235518\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249333381241012073557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:33:48Z","timestamp":1758267228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235518\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":179,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715249333381241012073557","relation":{},"ISSN":["1871-5249"],"issn-type":[{"type":"print","value":"1871-5249"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}